Search

Displaying results 6131 - 6140 of 6198 in total
  1. Drug

    Ronacaleret

    go.drugbank.com/drugs/DB05255
    Investigational

    Ronacaleret is a calcium-sensing receptor antagonist.

  2. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment o...

  3. Drug

    TY027

    go.drugbank.com/drugs/DB16500
    Investigational

  4. Drug

    CR665

    go.drugbank.com/drugs/DB05155
    Experimental

    CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists. In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal...

  5. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studyi...

  6. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...

  7. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.

  8. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.

  9. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

  10. Drug

    Muparfostat

    go.drugbank.com/drugs/DB05808
    Investigational

    Muparfostat (PI-88) is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic activity.